Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + mechlorethamine + vincristine + prednisone + procarbazine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
The MMOPP regimen is a combination chemotherapy protocol evaluated by the M.D. Anderson Cancer Center, specifically in a Phase II clinical trial (NCT00002463). This regimen was designed as a primary therapy for infants and young children with primitive neuroectodermal tumors (PNET) or high-grade astrocytomas to delay or avoid the need for cranial irradiation. It integrates high-dose methotrexate (HMTX) with the standard MOPP protocol, which consists of mechlorethamine, vincristine, procarbazine, and prednisone. Methotrexate acts as an antimetabolite by inhibiting dihydrofolate reductase, thereby disrupting DNA synthesis. Mechlorethamine and procarbazine serve as DNA alkylating agents, vincristine acts as a microtubule inhibitor to arrest mitosis, and prednisone is a corticosteroid that provides lympholytic effects and reduces cerebral edema.
- Other names
- MMOPP regimenMethotrexate-MOPPMOPP plus methotrexate
02
Targets
DHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on methotrexate + mechlorethamine + vincristine + prednisone + procarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + mechlorethamine + vincristine + prednisone + procarbazine.